TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Objective Response Rate (ORR) According to RECIST 1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: change in near visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in VFQ25 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: change in far visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage Change From Baseline in Overall VAS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Amygdala and hippocampus volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Amygdala and hippocampus function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Growth Modulation Index (GMI) Greater Than or Equal to 1.3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-Xa concentration maximum 0-24h (Cmax0-24h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Arm and Hand Recovery Stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of coronary artery calcium scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Degree of regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change-from-baseline in corrected QT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of proviral HIV-1 DNA in CD4 T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Positive screening of Fabry disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Genetic variants associated with arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Achieving Improvement in Personal and Social Performance
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Program acceptability to caregivers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Program acceptability to providers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reported and Observed Home Safety behaviors
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: therapeutical impact of reassessment strategy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mucosal Staining Efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms associated with chronic posterior laryngitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hip structural analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major Amputation or Revascularization (of the Index Leg)
Endpoint domain: Mortality/survival
Primary endpoint: Change in Ischemic Rest Pain (in the Index Leg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the Quality of Life Using the Vascular Quality of Life Questionnaire (VascuQol)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Self-reported adherence to INFb-1b
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Urine concentration of salmeterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Activity Volume: Right D1 Attempt Movement Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Activity Volume: Right Hand Grasp Overt/Attempt Movement Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Location of Peak Activity (X-coordinate) for Right D1 Attempt Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in symptomatology
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pouch status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite Outcome Measure (CV Death, Non-fatal MI, Non-fatal Stroke)
Endpoint domain: Mortality/survival
Primary endpoint: Validation of biosensor platform
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Patient's pain/discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: P2Y12 Reaction Unit (PRU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Platelet Aggregation Using Multiplate Analyzer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage re-growth of scalp hair loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: kidney function change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Participants With Wound Closure of the Treatment Sites at Three Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percent Area of the StrataGraft Treatment Site Requiring Autografting by Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Undigested wheat protein levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Skin Color
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in intragastric pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Conversion to multiport or open operation
Endpoint domain: Surgical and medical procedures outcomes
Primary endpoint: Reappearance of hiatal hernia and reflux
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean Change in Vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biering-Sørensen test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rapid reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Weekly Moderate-Vigorous Physical Activity Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of episodes of Adverse drug reaction (ADR's)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of episodes of Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Number of episodes of Serious Adverse Events (SAE's)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of episodes of Ocular Adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Ever had sex
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Contraceptive use at last intercourse
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Changes to contraceptive method in last year
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Ever visited doctor/clinic for birth control, exam, or STI
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Optimal flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percent Change From MRI Baseline in htTKV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Presence of a site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Oxygenation measured by the oxygen reserve index (ORI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of infections
Endpoint domain: Adverse events/effects
Primary endpoint: Oral health behaviors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: proportion of patients with clinical response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Practical performance in carrying out dressing procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sirtuin deacetylase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crank torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normal brain development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Controlled Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Attainment of blood pressure target (<130/80 mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Evaluation of left ventricular mass by echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diapason questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Study recruitment ability
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Montreal Stretch Reflex Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of prednisolone cream vs. betamethasone cream
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Safety of prednisolone cream vs. betamethasone cream
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D)
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Amount of blood loss during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Composite outcome of myocardial infarction, stroke, acute renal failure, pneumonia, sepsis, and death of any cause
Endpoint domain: Mortality/survival
Primary endpoint: Changes in performance on the Memory Intentions Test (MIST)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of suboxone doses taken
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of opiate-negative urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consolidation of episodic memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Psychomotor vigilance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: HPA Axis Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentile of glottic opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disengagement From Social Threat Cues
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Passive Thumb MP Hyperextension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic thumb MP Hyperextension (key pinch)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dynamic thumb MP position during cylindrical grasp
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Obsessive-Compulsive symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Movement disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Post-Surgical Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Progression (TTP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of an increase in SOFA-Score ≥3 points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death within 28 days
Endpoint domain: Mortality/survival
Primary endpoint: Change from baseline values in clinical laboratory assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline for Electrocardiogram (ECG) assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline values in vital sign assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: GSK1265744 concentration at 1 month post-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective test score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of participants with all-cause death
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with cardiovascular death events
Endpoint domain: Mortality/survival
Primary endpoint: Tendon structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Progression-free survival at 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Activities of daily living assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: pulmonary complication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: oro-pharyngeal swallowing efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Restless Legs Syndrome Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood concentrations of duloxetine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adverse pregnancy outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Computerized axial tomography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sweat distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiovascular profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: awake ambulatory systolic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Opioid Overdose Incidence
Endpoint domain: Mortality/survival
Primary endpoint: Receptiveness to Weight Management Interventions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Apnea hypopnea index >5 events per hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Time to recurrent intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Failure of CMV treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Clearance of Actinic Keratosis Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Parent and Teacher ADHD Rating Scale-IV
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Hepatitis C Viral Load Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with SVR defined as HCV RNA ≤ LOQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in RPQ Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in EVestG Field Potential's Features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of seizure detection system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: General discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Area Under the Curve 0 to Last Measurable Value (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total score of Pittsburgh Sleep Quality Index (PSQ)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change from Baseline in Echocardiographic Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Retention rate at 3 months
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acne scar severity grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Plasmatic concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: High risk assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Number of Ranibizumab Injections
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Two minute walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Treated Lesions With Achievement of ≤ 50% Residual Stenosis Without Adjunctive Therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Who Were Free From New-onset Major Adverse Events at 30 Days Post-treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Hamilton Anxiety Scale (HAM-A)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to continence after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of neuropathic symptoms and abnormal sensory examination findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Nerve fiber density at the leg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Endurance time during CWLT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance of MEI- and x-ray-images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of depression or anxiety disorders
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with undetectable viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cholesterol Medication Adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Maximum observed plasma concentration (Cmax) of cetirizine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curves to the last measurable concentration (AUCt)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Totalled score according to Part III of UPDRS (motor examination)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Totalled score according to Part II of UPDRS (activities of daily living)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose of Cabozantinib S-malate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Evaluable Patients With Dose Limiting Toxicities of Cabozantinib
Endpoint domain: Adverse events/effects
Primary endpoint: Clearance of Cabozantinib S-malate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pupil diameter > 6 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone union and callus formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Bone alignment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Eye-closed sway area (ECSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady State Visual Evoked Potential (ssVEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Biological Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Experiences of bodily changes in pregnancy and post-partum period
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Experiences with pregnancy health care- and post-partum service
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Quality of prenatal care
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain-Relief at 2 Hours Post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional Eating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in peripheral endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myofibrillar muscle protein synthesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concordance of lumefantrine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days absent from work due to sick leave
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in self-reported sick leave days
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Decrease breath Hydrogen and/or Methane production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Edema of face in the mandibular region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: aorto-associated complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement in Functional Outcome at Day 90
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning